openPR Logo
Press release

Migraine KOL Interview

08-08-2017 08:39 AM CET | Health & Medicine

Press release from: ReportsWorldwide

ReportsWorldwide has announced the addition of a new report title Migraine KOL Interview to its growing collection of premium market research reports.

For a Detailed description and table of contents of this report please click here:

February 08, 2017

We interviewed a neurologist based in the US who specializes in headache medicine to gauge his current and anticipated future use of acute and prophylactic agents in the treatment of episodic and chronic migraine. The drugs discussed include the anti-calcitonin gene-related peptide (CGRP) receptor monoclonal antibody AMG 334 (AMGN), anti-CGRP monoclonal antibodies ALD403 (ALDR), LY2951742 (LLY) and TEV-48125 (TEVA), small molecule CGRP receptor antagonists atogepant (AGN), ubrogepant (AGN) and telcagepant (MRK), small molecule 5HT1F receptor agonist lasmiditan (CLCD), Botox (AGN), triptans Imitrex (GSK), Maxalt (MRK) and Topamax (JNJ), Treximet (PTX), Atacand (AZN) and TI-001.

To Get Sample Copy of Report please visit @

About is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.

Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Migraine KOL Interview here

News-ID: 658653 • Views: 649

More Releases from ReportsWorldwide

World Deep Brain Stimulation Market Top Segments, Key Players Revenue, Growth Ra …
The World Deep Brain Stimulation Market is estimated to represent a global market of USD 751.8 million by 2017 with growth rate of 18.2%. Deep brain stimulation (DBS) procedure is primarily used for the treatment of neuropsychiatric disorders such as mood disorder, dementia, anxiety and others. The procedure involve the use of neurotransmitter (brain pacemaker) that enables to transmit electric impulses to the specific target of brain cells. Increasing incidence
New report explores the Gene Editing Market : Ushering The Next Breakthrough in …
Boston, MA ReportsWorldwide has announced the addition of a new report title Gene Editing The Next Breakthrough in Regenerative Medicine to its growing collection of premium market research reports. Genome editing is a type of genetic engineering in which DNA is replaced, inserted or deleted in a living organism's ggenome using engineered molecular scissors. Believed to be one of the great biotechnology breakthroughs, gene editing is a powerful tool in pharmaceutical research that
Global In-Building Wireless BTSController-based Small Cells Market Analysis and …
Boston, MA ReportsWorldwide has announced the addition of a new report title Global In-Building Wireless BTSController-based Small Cells Market Analysis and Forecast, 2017-2021 to its growing collection of premium market research reports. This report covers the leading in-building wireless enterprise BTS/controller-based small cells network equipment manufacturers: • CommScope/Airvana • Comba Telecom • Ericsson • Huawei Technologies • Nokia • SpiderCloud • ZTE Corporation This report covers the global market share for 2016 shipments as well as a forecast for 2017-2021. To view a detailed description and Table of

More Releases for CGRP

Mycophenolate Mofetil Market is Projected to Expand Steady Growth in Forecast Ye …
The global Mycophenolate Mofetil market size is projected to grow from 2021 to 2026. The demand for Mycophenolate Mofetil can be attributed to patient benefits, growth of the manufacturing sector, increasing production and growing capacity in healthcare industry, and healthy growth of pharmaceutical and food & beverage industry in developing countries, are supporting the growth of the Mycophenolate Mofetil market. Available Exclusive Sample Copy of this Report @ . Pandemic impact
Covid-19 Impact on Albendazole API Market 2021: Growth by Top Company - TEVA, Sh …
Global Albendazole API Market Synopsis: The exclusive research report on the Global Albendazole API Market 2021-2025 examines the market in detail along with focusing on significant market dynamics for the key players operating in the market. Global Albendazole API Industry research report offers granulated yet in-depth analysis of revenue share, market segments, revenue estimates and various regions across the globe. According to the market research study, Albendazole is a medication used for
Wearable wireless Patch Device Market 18% CGRP to 2023: Global Market Analysis, …
A wearable wireless healthcare patch is an all-in-one monitor that can measure heart rate, breathing patterns and other vital signs, offering both clinical and consumer healthcare uses. The Wearable wireless Patch Device Market to grow at a CAGR of +18% during the Forecast period. Wearable Medical Devices have grown phenomenally over the years in terms of their usage. Request Sample Copy of this report: Top Key Vendors: Fitbit, Garmin, Jawbone, Lifewatch, Misfit, Monica
Global Migraine Market 2018 Key Players: Eli Lilly & Company, Teva Pharmaceutica …
Migraine Market: adds “Migraine Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2024” reports to its database. Executive Summary FDA has recently approved first ever novel migraine preventive drug that resorts to prevention rather than treatment. It is posed as a breakthrough drug with immense market potential in upcoming years. The report “Global Migraine Market (By Nations-The US, the UK, Germany, France, Italy, Spain and Japan; Drugs- Triptan, CGRP,
In-Depth Analysis of Calcitonin Gene Related Peptide (CGRP) Pipeline and Therape …
Market Research Hub (MRH) has included a new extensive and fact-based research publication, titled "Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H1 2018" in its extensive research database. This study examines comprehensive information on the therapeutics under development for Calcitonin Gene Related Peptide, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Moreover, its pipeline analysis by companies
Global Market Report on Calcitonin Gene Related Peptide (CGRP)-Pipeline Review, …
"The Report Calcitonin Gene Related Peptide (CGRP)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. -" Calcitonin Gene Related Peptide (CGRP)-Calcitonin gene related peptide (CGRP) is a member of the calcitonin family of peptides. It exists in two forms alpha-CGRP and beta-CGRP. CGRP is produced in both peripheral and central neurons. CGRP is derived mainly from the cell bodies of